References
Original article
Pinto, C. et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(21)00404-6 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Benefit with ramucirumab in mesothelioma. Nat Rev Clin Oncol 18, 676 (2021). https://doi.org/10.1038/s41571-021-00563-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00563-4
- Springer Nature Limited